We undertook a randomized trial that compared treatment between the SGLT2i, canagliflozin and glimepiride, with the primary objective of assessing the effect of canagliflozin on N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in T2DM patients with chronic HF [13]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.